BioSpace News Archive

Indaptus Therapeutics, Inc. announces that the European Patent Office (EPO) has informed the company that it will grant a European patent related to the company’s platform technology, covering a composition that can be used in the prevention or treatment of viral infections.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.

Immutep Limited today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial.

4D Molecular Therapeutics announced clinical pipeline progress, updates to near-term milestones and organizational updates.

Recursion announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies’ fibrosis research collaboration.

Quanta Therapeutics today announced progress across its pipeline of KRAS-directed drug candidates, including U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance for QTX3034, a multi-KRAS inhibitor with G12D-preferring activity (G12D+ multi-KRAS), enabling the initiation of a Phase 1 clinical trial in the first quarter of 2024.

FibroBiologics, Inc. announced that it will attend the Biotech Showcase in San Francisco, CA from January 8-10, 2024.

Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global.

Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family of products.

ANGLE plc is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient’s cancer and how this may be treated.